Zhejiang U | College of Pharmaceutical Sciences | 中文版
     
     
PUBLICATION

    JOURNAL PAPER

    * Corresponding Authorship

    # Co-first Authorship

  1. Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, Y. Zhang, S. Li, F. Y. Yang, Q. Sun, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic Target Database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Research. 46(D1): D1121-D1127 (2018).
  2. F. Zhu*, X. X. Li, S. Y. Yang, Y. Z. Chen*. Clinical success of drug targets prospectively predicted by in-silico study. Trends in Pharmacological Sciences. Epub ahead of print. doi: 10.1016/j.tips.2017.12.002 (2018).
  3. W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to SNRIs' dual-targeting mechanism? The key role of TM6 domain in hSERT and hNET revealed by molecular dynamics simulation. ACS Chemical Neuroscience. Epub ahead of print. doi: 10.1021/acschemneuro.7b00490 (2018).
  4. W. W. Xue, P. P. Wang, G. Tu, F. Y. Yang, G. X. Zheng, X. F. Li, X. X. Li, Y. Z. Chen, X. J. Yao, F. Zhu*. Computational identification of the binding mechanism of triple reputake inhibitor amitifadine for the treatment of major depressive disorder. Physical Chemistry Chemical Physics. Epub ahead of print. doi: 10.1039/C7CP07869B (2018).
  5. C. Y. Yu, X. X. Li, H. Yang, Y. H. Li, W. W. Xue, Y. Z. Chen, L. Tao, F. Zhu*. Assessing the performances of protein function prediction algorithms from the perspectives of identification accuracy and false discovery rate. International Journal of Molecular Sciences. 19(1): 183 (2018).
  6. X. F. Li, X. X. Li, Y. H. Li, C. Y. Yu, W. W. Xue, J. Hu*, B. Li, P. P. Wang, F. Zhu*. What makes species productive of anti-cancer drugs? Clues from drugs’ species origin, druglikeness, target and pathway. Anti-Cancer Agents in Medicinal Chemistry. ACA-20171024067m, accepted (2018).
  7. X. T. Kong, H. Y. Sun, P. C. Pan, F. Zhu, Y. Y. Li, T. J. Hou*. Importance of protein flexibility on molecular recognition: a case study on type-I1/2 inhibitors of ALK.  Physical Chemistry Chemical Physics. Epub ahead of print. doi: 10.1039/c7cp08241j (2018).
  8. B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Research. 45(W1): 162-170 (2017).
  9. P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and non-addictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chemical Neuroscience. 8(6): 1416-1428 (2017).
  10. G. X. Zheng, W. W. Xue*, F. Y. Yang, Y. Zhang, Y. Z. Chen, X. J. Yao, F. Zhu*. Revealing vilazodone's binding mechanism underlying its partial agonism to 5-HT1A receptor in the treatment of major depressive disorder. Physical Chemistry Chemical Physics. 19(42): 28885-28896 (2017).
  11. P. P. Wang, T. T. Fu, X. Y. Zhang, F. Y. Yang, G. X. Zheng, W. W. Xue*, Y. Z. Chen, X. J. Yao, F. Zhu*. Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. BBA General Subjects. 1861(11A): 2766-2777 (2017).
  12. F. Y. Yang, T. T. Fu, X. Y. Zhang, J. Hu*, W. W. Xue*, G. X. Zheng, B. Li, Y. H. Li, X. J. Yao, F. Zhu*. Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters. Molecular Simulation. 43(13-16): 1089-1098 (2017).
  13. P. C. Pan, H. D. Yu, Q. L. Liu, X. T. Kong, H. Chen, J. A. Chen, Q. Liu, D. Li, Y. Kang, H. Y. Sun, W. F. Zhou, S. Tian, S. L. Cui, F. Zhu, Y. Y. Li, Y. Huang, T. J. Hou*. Combating drug-resistant mutants of ALK with potent and selective type-I1/2 inhibitors by stabilizing unique DFG-shifted loop conformation. ACS Central Science. 3(11): 1208-1220 (2017).
  14. T. Feng, F. Chen, Y. Kang, H. Y. Sun, H. Liu, D. Li, F. Zhu, T. J. Hou*. HawkRank: a new scoring function for protein-protein docking based on weighted energy terms. Journal of Cheminformatics. 9(1): 66 (2017).
  15. T. L. Lei, H. Y. Sun, Y. Kang, F. Zhu, H. Liu, W. F. Zhou, Z. Wang, D. Li, Y. Y. Li, T. J. Hou*. ADMET evaluation in drug discovery. 18. Reliable prediction of chemical-induced urinary tract toxicity by boosting machine learning approaches. Molecular Pharmaceutics. 14(11): 3935-3953 (2017).
  16. S. Tian, X. Wang, L. L. Li, X. H. Zhang, Y. Y. Li, F. Zhu, T. J. Hou*, X. C. Zhen*. Discovery of novel and selective adenosine A2A receptor antagonists for treating parkinson's disease through comparative structure-based virtual screening. Journal of Chemical Information and Modeling. 57(6): 1474-1487 (2017).
  17. X. T. Kong, H. Y. Sun, P. C. Pan, D. Li, F. Zhu, S. Chang, L. Xu, Y. Y. Li*, T. J. Hou*. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study. Scientific Reports. 7: 9088 (2017).
  18. J. Y. An, X. D. Pei, Z. L. Zang, Z. Zhou, J. T. Hu, X. Zheng, Y. Zhang, J. J. He, L. Duan, R. F. Shen, W. H. Zhang, F. Zhu, S. Li*, H. Yang*. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. Oncotarget. 8(23): 37538-37549 (2017).
  19. P. Zhang, L. Tao, X. Zeng, C. Qin, S. Chen, F. Zhu, Z. Li, Y. Jiang, W. Chen, Y. Z. Chen*. A protein network descriptor server and its use in studying protein, disease, metabolic and drug targeted networks. Briefings in Bioinformatics. 18(6): 1057-1070 (2017).
  20. P. Zhang, L. Tao, X. Zeng, C. Qin, S. Y. Chen, F. Zhu, S. Y. Yang, Z. R. Li, W. P. Wang, Y. Z. Chen*. PROFEAT update: a protein features web-server with added facility to compute network descriptors for studying omics-derived networks. Journal of Molecular Biology. 429(3): 416-425 (2017).
  21. H. Yang, C. Qin, Y. H. Li, L. Tao, J. Zhou, C. Y. Yu, F. Xu, Z. Chen, F. Zhu*, Y. Z. Chen*. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Research. 44(D1): 1069-1074 (2016).
  22. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.87% in 2017.
    • The Percentile in Subject Area shown in InCites™ was 0.71% in 2018.

  23. B. Li, J. Tang, Q. X. Yang, X. J. Cui, S. Li, S. J. Chen, Q. X. Cao, W. W. Xue, N. Chen, F. Zhu*. Performance evaluation and online realization of data-driven normalization methods used in LC/MS based untargeted metabolomics analysis. Scientific Reports. 6: 38881 (2016).
  24. W. W. Xue, P. P. Wang, B. Li, Y. H. Li, X. F. Xu, F. Y. Yang, X. J. Yao, Y. Z. Chen, F. Xu, F. Zhu*. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Physical Chemistry Chemical Physics. 18(4): 3260-3271 (2016).
  25. Successful Validation of the Constructed Model:
    • The cocrystallized structure published (Nature. 532(7599):334-9, 2016) right after our publication was highly consistent with the drug-target binding mode discovered in this study.

  26. G. X. Zheng, W. W. Xue, P. P. Wang, F. Y. Yang, B. Li, X. F. Li, Y. H. Li, X. J. Yao, F. Zhu*. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study. Scientific Reports. 6: 26883 (2016).
  27. Y. H. Li, P. P. Wang, X. X. Li, C. Y. Yu, H. Yang, J. Zhou, W. W. Xue, J. Tan, F. Zhu*. The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective. PLoS ONE. 11(11): e0165737 (2016).
  28. J. Y. Xu, P. P. Wang, H. Yang, J. Zhou, Y. H. Li, X. X. Li, W. W. Xue, C. Y. Yu, Y. B. Tian, F. Zhu*. Comparison of FDA approved kinase targets to clinical trial ones: insights from their system profiles and drug-target interaction networks. Biomed Research International. 2016: 2509385 (2016).
  29. Y. H. Li, J. Y. Xu, L. Tao, X. F. Li, S. Li, X. Zeng, S. Y. Chen, P. Zhang, C. Qin, C. Zhang, Z. Chen, F. Zhu*, Y. Z. Chen. SVM-Prot 2016: a web-server for machine learning prediction of protein functional families from sequence irrespective of similarity. PLoS ONE. 11(8): e0155290 (2016).
  30. X. Zheng, S. Li, Z. L. Zang, J. T. Hu, J. Y. An, X. D. Pei, F. Zhu, W. H. Zhang*, H. Yang*. Evidence for possible role of toll-like receptor 3 mediating virus-induced progression of pituitary adenomas. Molecular and Cellular Endocrinology. 426: 22-32 (2016).
  31. L. Tao#, F. Zhu#, F. Xu, Z. Chen, Y. Y. Jiang*, Y. Z. Chen*. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacological Research. 102: 123-131 (2015).
  32. L. Tao, P. Zhang, C. Qin, S. Y. Chen, C. Zhang, Z. Chen, F. Zhu, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Advanced Drug Delivery Reviews. 86: 83-100 (2015).
  33. L. Tao, F. Zhu, C. Qin, C. Zhang, S. Y. Chen, P. Zhang, C. L. Zhang, C. Y. Tan, C. M. Gao, Z. Chen, Y. Y. Jiang*, Y. Z. Chen*. Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites. Scientific Reports. 5: 9325-9334 (2015).
  34. P. P. Wang, F. Y. Yang, H. Yang, X. F. Xu, D. Liu, W. W. Xue, F. Zhu*. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. Bio-Medical Materials and Engineering. 26 Suppl 1: S2233-2239 (2015).
  35. Y. P. Jing, B. Li, N. Chen, X. F. Li, J. Hu, F. Zhu*. The discrimination of learning styles by bayes-based statistics: an extended study on ILS system. Control and Intelligent System. 43(2) (2015).
  36. L. Tao, F. Zhu, C. Qin, C. Zhang, F. Xu, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Nature's contribution to today's pharmacopeia. Nature Biotechnology. 32(10): 979-980 (2014).
  37. P. P. Wang, J. Hu, Y. H. Li, F. Xu, F. Zhu*, Y. Z. Chen. Identification of novel neurotensin receptor 1 inhibitors by combinatorial support vector machine. Journal of Pharmacology Clinical Toxicology. 2(2): 1024-1031 (2014).
  38. C. Zhang, C. Qin, L. Tao, F. Zhu, S. Y. Chen, P. Zhang, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. A resource for facilitating the development of tools in the education and implementation of genomics-informed personalized medicine. Clinical Pharmacology & Therapeutics. 95(6): 590-591 (2014).
  39. C. Qin, C. Zhang, F. Zhu, F. Xu, S. Y. Chen, P. Zhang, Y. H. Li, S. Y. Yang, Y. Q. Wei, L. Tao*, Y. Z. Chen*. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Research. 42(D1): 1118-1123 (2014).
  40. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2017.

  41. X. Liu, F. Zhu, X. H. Ma, Z. Shi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Predicting targeted polypharmacology for drug repositioning and multi-target drug discovery. Current Medicinal Chemistry. 20(13): 1646-1661 (2013).
  42. F. Zhu, X. H. Ma, C. Qin, L. Tao, X. Liu, Z. Shi, C. L. Zhang, Y. Y. Jiang*, Y. Z. Chen*. Drug discovery prospect from untapped species: indications from approved natural product drugs. PLoS ONE. 7(7): e39782 (2012).
  43. X. H. Ma, F. Zhu, X. Liu, Z. Shi, J. X. Zhang, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Virtual screening methods as tools for drug lead discovery from large chemical libraries. Current Medicinal Chemistry. 19(32): 5562-5571 (2012).
  44. J. X. Zhang, J. Jia, F. Zhu, X. H. Ma, B. C. Han, X. N. Wei, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular BioSystems. 8: 2645-2656 (2012).
  45. F. Zhu, Z. Shi, C. Qin, L. Tao, F. Xu, L. Zhang, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Research. 40(D1): D1128-D1136 (2012).
  46. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.31% in 2017.
    • The Percentile in Subject Area shown in InCites™ was 0.62% in 2018.

    Highlights by Experts in Subject Area:

    • "FACULTYof1000" as "the top 2% of published articles in biology and medicine" and "a most useful resource for scientists and companies working on drug discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations".
    • Prof. Chris Southan in his blog as "Therapeutic Target Database in PubChem".

  47. H. B. Rao*, Y. Y. Wang, X. Y. Zeng, X. X. Wang, Y. Liu, J. J. Yin, H. He, F. Zhu, Z. R. Li*. In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches. Chemometrics and Intelligent Laboratory Systems. 118: 271-279 (2012).
  48. H. B. Rao*, X. Y. Zeng, Y. Y. Wang, H. He, F. Zhu, Z. R. Li, Y. Z. Chen. Identification of DNA-Adduct formation of small molecules by molecular descriptors and machine learning methods. Molecular Simulation. 34(4): 259-273 (2012).
  49. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. PNAS. 108(31): 12943-12948 (2011).
  50. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.91% in 2017.
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2018.
    Highlights by Experts in Subject Area: Media Coverage & News Report:

  51. H. B. Rao#, F. Zhu#, G. B. Yang, Z. R. Li*, Y. Z. Chen. Update of PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequences. Nucleic Acids Research. 39(suppl 2): W385-390 (2011).
  52. X. Liu, F. Zhu, X. H. Ma, L. Tao, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. The therapeutic target database: an internet resource for the primary targets of approved, clinical trial and experimental drugs. Expert Opinion on Therapeutic Targets. 15(8): 903-912 (2011).
  53. F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Research. 38(suppl 1): D787-D791 (2010).
  54. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 2.95% in 2017.
    • The Percentile in Subject Area shown in InCites™ was 2.97% in 2018.

  55. F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profile of successful targets. Journal of Pharmacology and Experimental Therapeutics. 330(1): 304-315 (2009).
  56. Successful Validation of the Constructed Model:
    • Pasireotide targeting Somatostatin receptor 1 was approved by FDA in 2011.
    • Fingolimod targeting S1P receptor was approved by FDA in 2010.
    • Ecallantide targeting Plasma Kallikrein was approved by FDA in 2009.
    • Cinryze targeting C1 esterase was approved by FDA in 2009.
    • Icatibant targeting BK-2 receptor was approved by FDA in 2008.
    • Plerixafor targeting CXCR4 was approved by FDA in 2008.

  57. J. Jia, F. Zhu, X. H. Ma, Z. W. Cao, Y. X. Li, Y. Z. Chen*. Mechanisms of drug combinations from interaction and network perspectives. Nature Reviews Drug Discovery. 8(2): 111-128 (2009).
  58. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.39% in 2017.
    • The Percentile in Subject Area shown in InCites™ was 1.13% in 2018.
  59. X. H. Ma, J. Jia, F. Zhu, Y. Xue, Z. R. Li, Y. Z. Chen*. Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. Combinatorial Chemistry & High Throughput Screening. 12(4): 344-357 (2009).
  60. F. Zhu, L. Y. Han, X. Chen, H. H. Lin, S. Ong, B. Xie, H. L. Zhang, Y. Z. Chen*. Homology-free prediction of functional class of proteins and peptides by support vector machines. Current Protein & Peptide Science. 9: 70-95 (2008).
  61. F. Zhu, C. J. Zheng, L. Y. Han, B. Xie, J. Jia, X. Liu, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Current Molecular Pharmacology. 1(3): 213-232 (2008).
  62. L. Y. Han, X. H. Ma, H. H. Lin, J. Jia, F. Zhu, Y. Xue, Z. R. Li, Z. W. Cao, Z. L. Ji, Y. Z. Chen*. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. Journal of Molecular Graphics and Modelling. 26(8): 1276-1286 (2008).
  63. L. Y. Han, C. J. Zheng, B. Xie, J. Jia, X. H. Ma, F. Zhu, H. H. Lin, X. Chen, Y. Z. Chen*. Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. Drug Discovery Today. 12(7-8): 304-313 (2007).
  64. H. H. Lin, L. Y. Han, C. W. Yap, Y. Xue, X. H. Liu, F. Zhu, Y. Z Chen*. Prediction of factor Xa inhibitors by machine learning methods. Journal of Molecular Graphics and Modelling. 26(2): 505-518 (2007).
  65. R. Li, Y. Chen, L. B. Cui, F. Zhu, J. Zhou, D. H. Liu*, S. Liu, X. S. Zhang. Effect of number of unit cells of FCC photonic crystal on property of band gaps. Acta Physica Sinica. 55(01): 0188-04 (2006).



    HOSTED CONFERENCE AND SYMPOSIUM

  1. F. Zhu is the Chairman of the Symposium IV Session -7 for Asian Federation for Pharmaceutical Sciences Conference 2017. Xiamen University, Xiamen, P. R. China (2017).
  2. F. Zhu is the Member of the Academic Committee for The 14th National Symposium of Computer & Computational Chemistry. Nanjing University, Nanjing, P. R. China (2017).
  3. F. Zhu is the Member of the Academic Committee for The Second CCF Bioinformatics Conference (CBC-2017). Central South University, Changsha, P. R. China (2017).
  4. F. Zhu is the Chairman of the sub-conference 103 (multi-target and protein-protein interaction) for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  5. F. Zhu is the Vice-chairman of the 6th theme (study on drug transporter and PK/PD) for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016)
  6. F. Zhu is the Chair of the Organizing Committee and the Member of the Academic Committee for The 2nd Symposium on Bioinformatics and Drug Design. Chongqing University, Chongqing, P. R. China (2016).
  7. F. Zhu is the Member of the Academic Committee for The 13th National Symposium of Computer & Computational Chemistry. Sun Yat-sen University, Guangzhou, P. R. China (2015).
  8. F. Zhu is the Member of the Organizing Committee for International Symposium on Natural Product Synthesis and Innovative Process Methods for Drug Manufacture. Chongqing University, Chongqing, P. R. China (2012).



    INVITED SPEAKER OF INTERNATIONAL AND DOMESTIC CONFERENCE

  1. F. Zhu*. Next Generation Innovative Therapeutic Target from NOREVA. Invited speaker of international conference for Asian Federation for Pharmaceutical Sciences Conference 2017Xiamen University, Xiamen, P. R. China (2017).
  2. F. Zhu*. Target Identification Assisted by Big-data Analyzing Tools. Invited speaker of domestic conference for The 14th National Symposium of Computer & Computational Chemistry. Nanjing University, Nanjing, P. R. China (2017).
  3. F. Zhu*. Drug Design and Big-data Platform. Invited speaker of domestic conference for The 5th Academic Forum for Postgraduates. Sichuan University, Chengdu, P. R. China (2017).
  4. F. Zhu*. Identification of Next Generation Innovative Therapeutic Target from OMICs Data. Invited keynote speaker of domestic conference for 2017 Symposium on Pharmaceutical Chemistry of the Yangtze River Delta Metropolitan Region. Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, P. R. China (2017).
  5. W. W. Xue*, F. Zhu*. What Contributes to SNRIs’ Dual-targeting Mechanism? The Key Role Played by TM6 Domain. Invited speaker of domestic conference for The Second Conference on Innovative Drug Research and Application. Nanjing Biotech and Pharmaceutical Valley, Nanjing, P. R. China (2017).
  6. F. Zhu*. Normalization and evaluation of metabolomics and proteomics data from multiple perspectives. Invited speaker of domestic conference for Bioinformatics and Intelligent Information Processing Academic Conference 2017 (BIIP2017). Shanghai Jiao Tong University, Shanghai, P. R. China (2017).
  7. F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Invited speaker of domestic conference for The Fifth Young Scholars Forum for Interdisciplinary Researches in Mathematics, Computer Sciences and Biological Sciences. Academy of Mathematics and System Science, Chinese Academy of Sciences, Beijing, P. R. China (2017).
  8. F. Zhu*. Normalization and evaluation of MS-based metabolomics data from multiple perspectives. Invited speaker of domestic conference for The 2017 (the second) Conference on Precision and Future Medicine. Zhejiang University, Hangzhou, P. R. China (2017).
  9. F. Zhu*. Large-scale Metabolomics Data Analysis. Invited speaker of domestic conference for China Society of Biotechnology Young Scientists Forum II . South China University of Technology, Guangzhou, P. R. China (2017).
  10. F. Zhu*. Bioinformatics Strategies in Precision Medicine. Invited speaker of international conference for The 2016 Symposium of Guanghua Young Distinguished Scholars . Fudan University, Shanghai, P. R. China (2016).
  11. F. Zhu*. Insight into the pathogenesis of pituitary adenomas by analyzing trans-omic data. Invited speaker of international conference for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  12. F. Zhu*. Metabolomics meta-analysis by MMEASE. Invited speaker of international conference for the 1st International Symposium on Targeted Therapeutics and Molecular Medicine (ISTTMM 2016). Chongqing University of Arts and Sciences, Chongqing, P. R. China (2016).
  13. W. W. Xue, F. Zhu*. Molecular dynamics study and comparison on the binding modes of SSRIs, sNRIs and SNRIs antidepressants. Invited speaker of international conference for BIT’s 6th Annual International Congress of Medichem-2016 (ICM-2016). China Pharmaceutical University, Nanjing, P. R. China (2016).
  14. G. X. Zheng, W. W. Xue, F. Zhu*. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors from molecular dynamics study. Invited speaker of international conference for The 4th International Conference on Molecular Simulation (ICMS 2016). Shanghai Jiao Tong University, Shanghai, P. R. China (2016).
  15. F. Zhu*. Normalization and Meta-analysis of Metabolomics Data. Invited speaker of domestic conference for The 7th National Conference on Bioinformatics & System Biology. University of Electronic Science and Technology of China, Chengdu, P. R. China (2016).
  16. F. Zhu*. Insight into the Pathogenesis of Pituitary Adenomas by Meta-analysis of Transcriptomic and Metabolomic Data. Invited speaker of domestic conference for The 2016 Conference on Precision Medicine. Xian Jiaotong University, Xian, P. R. China (2016).
  17. F. Zhu*. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Invited speaker of international conference for The 12th Sino-US Chemistry Professors Conference. Sun Yat-sen University, Guangzhou, P. R. China (2016).
  18. F. Zhu*. Discovering the stable marker identification methods for metabonomics study. Invited speaker of international conference for The 2016 Symposium of International Young Distinguished Scholars. Tongji University, Shanghai, P. R. China (2016).
  19. F. Zhu*. Design of multi-target anticancer drugs by analyzing the protein-protein interaction network of cancer. Invited speaker of domestic conference for The 2nd Symposium on Bioinformatics and Drug Design. Chongqing University, Chongqing, P. R. China (2016).
  20. F. Zhu*. Meta-analysis of Metabolomic data. Invited speaker of domestic conference for The 2016 Conference on Bioinformatics and Intelligent Information Processing (BIIP2016). Jilin University, Jilin, P. R. China (2016).
  21. F. Zhu*. MMEASE: a web-server for Meta-analysis of Metabolomic data by Enhanced metabolite Annotation, marker Selection and Enrichment analysis. Invited speaker of domestic conference for The 30th Academic Annual Conference of the Chinese Chemical Society. Dalian University of Technology, Dalian, P. R. China (2016).
  22. F. Zhu*. Identifying the metabonomics biomarkers. Invited speaker of domestic conference for The 2016 Academic Salon of Shanghai Society for Bioinformatics. Fudan University, Shanghai, P. R. China (2016).
  23. F. Zhu*. Insight into the pathogenesis of pituitary adenomas by meta-analysis of transcriptomic data. Invited speaker of domestic conference for The 2016 Symposium of Big Data and Precision Biomedical Informatics. Shanghai Jiao Tong University, Shanghai, P. R. China (2016).
  24. W. W. Xue and F. Zhu*. Identification of multi-target drug against remote target pair using combinatorial support vector mechine method. Invited speaker of domestic conference for The 13th National Symposium of Computer & Computational Chemistry. Sun Yat-sen University, Guangzhou, P. R. China (2015).
  25. F. Zhu*. Future bioprospecting: from the clustered patterns of species origins of nature-derived drugs. Invited speaker of international conference for The 6th International Conference of Molecular Simulation and Applied Information Technologies (6th-ICMS&I). China Pharmaceutical University, Nanjing, P. R. China (2012).
  26. F. Zhu*. Drug discovery prospect from untapped species: indications from approved natural product drugs. Invited speaker of international conference for International Symposium on Natural Product Synthesis and Innovative Process Methods for Drug Manufacture. Chongqing University, Chongqing, P. R. China (2012).
  27. F. Zhu*. Identification of next generation innovative therapeutic targets: clues from genetic, structural, physicochemical and system profile of successful ones. Invited speaker of international conference for Singapore Symposium on Computational Biology 2009 (SYMBIO2009). National University of Singapore, Singapore, Singapore (2009).



    INVITED ACADEMIC VISIT AND PRESENTATION

  1. F. Zhu*. Bioinformatics tools applied to the research field of brain science. Invited academic visit by Prof. Bo-Chu Wang to Bioengineering College, Chongqing University, Chongqing, P. R. China (2016).
  2. F. Zhu*. Comprehensive assessment of the popular normalization methods used in metabonomics study. Invited academic visit by Prof. Yu-Yang Jiang to Graduate School at Shenzhen, Tsinghua University, Shenzhen, P. R. China (2016).
  3. W. W. Xue and F. Zhu*. Extension of bioinformatics to the fields of brain sciences: metabonomics study of pituitary adenomas and design of multi-target antidepressants. Invited academic visit by Prof. Han-Bing Rao to Faculty of Science, Sichuan Agricultural University, Yaan, P. R. China (2016).
  4. W. W. Xue and F. Zhu*. Design of multi-target anticancer drugs by analyzing the protein-protein interaction network of cancer. Invited academic visit by Prof. Xiao-Jun Yao to School of Pharmacy, Lanzhou University, Lanzhou, P. R. China (2014).
  5. F. Zhu*. Computer-aided drug design based on the complex biological network of cancer. Invited academic visit by Prof. Cheng-Zhi Huang to College of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, P. R. China (2014).
  6. F. Zhu*. Identification of multi-target anticancer leads using combinatorial machine learning methods. Invited academic visit by Prof. Wei Wang to State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, P. R. China (2013).
  7. F. Zhu*. Design of anticancer leads and testing of their bioactivities. Invited academic visit by Prof. Da-He Liu to Department of Physics, Beijing Normal University, Beijing, P. R. China (2013).
  8. F. Zhu*. Find target and design bullet for the complex network disease - cancer. Invited academic visit by Prof. Ying Xue to College of Chemistry, Sichuan University, Chengdu, P. R. China (2013).
  9. F. Zhu*. Targets! Bullets! Computer-aided drug design from the network medicine perspective. Invited academic visit by Prof. Han-Bing Rao to Faculty of Science, Sichuan Agricultural University, Yaan, P. R. China (2013).
  10. F. Zhu*. Bioinformatics identification of anticancer drug targets. Invited academic visit by Prof. Kun-Xian Shu to School of Bioinformatics, Chongqing University of Posts and Telecommunications, Chongqing, P. R. China (2013).
  11. F. Zhu*. Clustered patterns of species origins of active ingredients in the traditional chinese medicine. Invited academic visit by Prof. Qi-Ni Qian to Chongqing Institute of Medicinal Plant Cultivation, Chongqing Institute of Medicinal Plant Cultivation, Chongqing, P. R. China (2013).

IDRB: Innovative Drug Research and Bioinformatics Group

visits since 2012
All rights are reserved by: Innovative Drug Research and Bioinformatics Group (IDRB)
College of Pharmaceutical Sciences, Zhejiang University
Hangzhou, P.R. China, 310058.
Contact number: (86-571)88208444

Last Update: